

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexandria, Virgnia 22313-1450 www.urpto.gov

DATE MAILED: 08/13/2003

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/040,394	01/09/2002	Jorn Borch Soe	674509-2045.1	3685	
20999	7590 08/13/2003				
FROMMER LAWRENCE & HAUG			EXAMINER		
745 FIFTH A NEW YORK	VENUE- 10TH FL. , NY 10151		HENDRICKS	HENDRICKS, KEITH D	
			ART UNIT	PAPER NUMBER	
			1761		

Please find below and/or attached an Office communication concerning this application or proceeding.

				-/j				
	Application N	0.	Applicant(s)	•/				
	10/040,394		SOE ET AL.					
Office Action Summary	Examiner		Art Unit					
	Keith Hendric		1761					
The MAILING DATE of this communication app Period for Reply	pears on the co	er sheet with the c	orrespondence ad	dress				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a repl If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, he y within the statutory will apply and will exp a cause the application	owever, may a reply be tin minimum of thirty (30) day ire SIX (6) MONTHS from n to become ABANDONE	nely filed s will be considered timely the mailing date of this co D (35 U.S.C. § 133).	/. mmunication.				
1) Responsive to communication(s) filed on 201	<u>May 2003</u> .							
2a) This action is FINAL . 2b) ☐ Th	nis action is non	-final.						
3) Since this application is in condition for allows				e merits is				
closed in accordance with the practice under ${\bf Disposition\ of\ Claims}$	<i>Ex рапе Quay</i>	e, 1935 C.D. 11, 4	103 U.G. 213.					
4) Claim(s) 38,40-47,50,51,53 and 54 is/are pen								
4a) Of the above claim(s) is/are withdra	wn from consid	eration.						
	5) Claim(s) is/are allowed.							
6) Claim(s) 38,40-47,50,51,53 and 54 is/are rejection.	cted.							
7) Claim(s) is/are objected to.								
8) Claim(s) are subject to restriction and/or election requirement.								
Application Papers	or.							
9) The specification is objected to by the Examiner.								
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.								
If approved, corrected drawings are required in re			•					
12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign	n priority under	35 U.S.C. § 119(a	a)-(d) or (f).					
a) All b) Some * c) None of:								
1. Certified copies of the priority documents have been received.								
2. Certified copies of the priority documents have been received in Application No								
 Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachment(s)	,							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 1	4) [5) [5) [6) [Notice of Informal	y (PTO-413) Paper No Patent Application (PT					

Application/Control Number: 10/040,394

Art Unit: 1761

DETAILED ACTION

Election/Restrictions

With respect to claim 47, applicants' comments at pages 6-8 of the response of May 20, 2003, have been considered persuasive. It is noted for the record, however, that claim 47 is limited to the scope encompassed by applicants' specific comments therein, and with respect to those limitations in the specification concerning a "dough additive component", with the lipase enzyme claimed.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Applicants' arguments filed May 20, 2003 have been fully considered but they are not persuasive. At pages 11-12, applicants state that "no terminal disclaimer is necessary", because the double patenting rejections are "merely provisional", and thus "the Examiner can... drop the rejection in this case." Applicants state that (provisional) double patenting rejections may be made in the co-pending applications over any allowed claims in the instant case.

This, however, is not deemed persuasive, and is not an accurate assessment of the rejections at hand. As stated above, a timely-filed proper terminal disclaimer may be submitted to overcome the rejection, provided the conflicting application or patent is shown to be commonly owned with this application. Applicants have performed neither task. There is no exception or provision for applicants' proposed scenario. In part, these requirements are set forth for the situation where applications are not commonly-owned, and thus inventions may be sold to separate entities. Evidence of common ownership is required before the rejection may be withdrawn, along with a properly-filed terminal disclaimer.

Application/Control Number: 10/040,394 Page 3

Art Unit: 1761

i) Claims 38-46, 50-54 and 47 remain provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-10 of copending Application No. 09/727,852. Although the conflicting claims are not identical, they are not patentably distinct from each other because each application claims the use of an enzyme (lipase) in dough, which hydrolyzes "compounds including a triglyceride, a glycolipid and a phospholipid."

ii) Claims 38-46, 50-54 and 47 remain provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-10 of copending Application No. 09/723,253. Although the conflicting claims are not identical, they are not patentably distinct from each other because each application claims the use of an enzyme (lipase) in dough, which hydrolyzes "compounds including a triglyceride, a glycolipid and a phospholipid."

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

** NOTE: Although not required, applicants are again requested to supply the Office with the serial numbers of all related co-pending or allowed applications which pertain to the subject matter contained herein, including any pertaining to the enzymes themselves. This request was made in the `253 application in August of 2001, yet no mention of the instant application has been made by applicants since the filing of this application.

Application/Control Number: 10/040,394

Art Unit: 1761

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Keith Hendricks whose telephone number is (703) 308-2959. The examiner can normally be reached on M-F (8:30am-6pm); First Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Milton Cano can be reached on (703) 308-3959. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9310 for regular communications and (703) 872-9565 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0661.

KEITH HENDRICKS PRIMARY EXAMINER